SCHEMBL2889176

SCHEMBL2889176

O=S(=O)(Nc1cccc(CO)c1)c1ccc(Br)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.69
HSD17B2 P37059 1/20 0.67
ITGA1 P56199 1/20 0.59
ALDH1A1 P00352 1/20 0.57
HTR6 P50406 5/20 0.55
CYP19A1 P11511 2/20 0.54
AR P10275 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
EGFR P00533 1/20 0.50
ERBB2 P04626 1/20 0.50
MAPT P10636 1/20 0.50
PHGDH O43175 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
HTT P42858 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
PKM P14618 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13028493 0.96 IKBKB (0.64) IKBKBHSD17B2ITGA1ALDH1A1HTR6
SCHEMBL13028569 0.89 HSD17B2 (0.63) IKBKBHSD17B2ITGA1HTR6CYP19A1
SCHEMBL14425657 0.86 HTR6 (0.72) IKBKBALDH1A1HTR6SMN1; SMN2PHGDH
SCHEMBL13028509 0.85 IKBKB (0.56) IKBKBHSD17B2ITGA1ALDH1A1HTR6
SCHEMBL6973491 0.85 IKBKB (0.69) IKBKBHSD17B2ALDH1A1HTR6CYP19A1
SCHEMBL2894635 0.85 HSD17B2 (0.59) IKBKBHSD17B2ITGA1HTR6CYP19A1
SCHEMBL2889311 0.84 IKBKB (0.67) IKBKBALDH1A1HTR6PHGDH
SCHEMBL2888723 0.82 IKBKB (0.62) IKBKBHSD17B2ALDH1A1HTR6MAPT
SCHEMBL2891992 0.82 IKBKB (0.68) IKBKBHSD17B2ALDH1A1HTR6CYP19A1
SCHEMBL15232982 0.82 UCHL1 (0.58) IKBKBHSD17B2ITGA1HTR6CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137141-B1 BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS UNIV ABERDEEN (GB) 2015-12-02 EP disclosed
EP-2137141-B1 BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS UNIV ABERDEEN (GB) 2015-12-02 EP disclosed
US-8524778-B2 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents PIMCO 2664 LIMITED (GB) 2013-09-03 US disclosed
US-8524778-B2 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents PIMCO 2664 LIMITED (GB) 2013-09-03 US disclosed
US-8524778-B2 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents PIMCO 2664 LIMITED (GB) 2013-09-03 US disclosed
US-20100286266-A1 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2010-11-11 US disclosed
US-20100286266-A1 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2010-11-11 US disclosed
US-20100286266-A1 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2010-11-11 US disclosed
EP-2137141-A1 BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS The University Court of The University of Aberdeen (GB) 2009-12-30 EP disclosed
WO-2008114022-A1 BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2008-09-25 WO disclosed
WO-2008114022-A1 BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286266-A1 Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents ARSA, SOST, AHR IKBKB 139/4885HSD17B2 3104/4885ITGA1 2317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.